Actelion Pharmaceuticals Ltd (VTX:ATLN) Corporate news announcement processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------
Dear member of the investment community
Actelion Ltd will announce the financial full year 2008 results on Thursday, 19 February 2009, at 07.00 CET / 01.00 EST / 06.00 GMT.
The same day, the company hosts Actelion Day 2009. This event will be a combination of Actelion's annual Media and Analyst Conference (M&A Day) and its Research and Development Day (R&D Day).
The event will be available via webcast, however, questions will be restricted to audience members only.
For those of you who have not received a personalized invitation as a buy- or sell-side analyst and wishing to attend the event in person, we kindly ask to send an e-mail to investor.relations@actelion.com. Please note that space is limited.
Actelion will host an Investor Conference Call / Webcast as follows:
Date/Time:
19 February 2009 12.30 hrs - 16.30 hrs Basel (CEST) 11.30 hrs - 15.30 hrs U.K. (BST) 06.30 a.m. - 10.30 a.m. U.S. (EDT)
Conference Call Connect #: Dial-in participants should start calling the number below 10-15 minutes before the Conference is due to start.
Dial: Europe: +41 44 580 64 03 U.K.: +44 207 153 91 54 U.S.: +1 866 928 60 44
Participant's mode: Listen-Only. Questions will be restricted to audience members only.
Webcast Access: Webcast participants should visit the Actelion website for further details http://www.actelion.com/ 10-15 minutes before the conference is due to start.
Participant's mode: Listen-Only. Questions will be restricted to audience members only.
Webcast Replay: The archived Investor Webcast will be available for replay through http://www.actelion.com/ approximately 60 minutes after the call has ended.
For further information please contact: Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil Roland Haefeli Vice President, Head of Investor Relations & Public Affairs +41 61 565 62 62 +1 650 624 69 36 http://www.actelion.com
--- End of Message ---
Actelion Pharmaceuticals Ltd Gewerbestrasse 16 Allschwil Switzerland
WKN: 936767; ISIN: CH0010532478; Index: SBIOM, SLIFE, SMCI, SMIEXP, SMIM, SPI, SPIEX; Listed: Main Market in SIX Swiss Exchange;
LINK: http://hugin.info/131801/R/1284612/287837.pdf
Actelion Pharmaceuticals Ltd
http://www.actelion.com
ISIN: CH0010532478
Stock Identifier: XSWX.ATLN
US: OTC:ALIOF
Dear member of the investment community
Actelion Ltd will announce the financial full year 2008 results on Thursday, 19 February 2009, at 07.00 CET / 01.00 EST / 06.00 GMT.
The same day, the company hosts Actelion Day 2009. This event will be a combination of Actelion's annual Media and Analyst Conference (M&A Day) and its Research and Development Day (R&D Day).
The event will be available via webcast, however, questions will be restricted to audience members only.
For those of you who have not received a personalized invitation as a buy- or sell-side analyst and wishing to attend the event in person, we kindly ask to send an e-mail to investor.relations@actelion.com. Please note that space is limited.
Actelion will host an Investor Conference Call / Webcast as follows:
Date/Time:
19 February 2009 12.30 hrs - 16.30 hrs Basel (CEST) 11.30 hrs - 15.30 hrs U.K. (BST) 06.30 a.m. - 10.30 a.m. U.S. (EDT)
Conference Call Connect #: Dial-in participants should start calling the number below 10-15 minutes before the Conference is due to start.
Dial: Europe: +41 44 580 64 03 U.K.: +44 207 153 91 54 U.S.: +1 866 928 60 44
Participant's mode: Listen-Only. Questions will be restricted to audience members only.
Webcast Access: Webcast participants should visit the Actelion website for further details http://www.actelion.com/ 10-15 minutes before the conference is due to start.
Participant's mode: Listen-Only. Questions will be restricted to audience members only.
Webcast Replay: The archived Investor Webcast will be available for replay through http://www.actelion.com/ approximately 60 minutes after the call has ended.
For further information please contact: Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil Roland Haefeli Vice President, Head of Investor Relations & Public Affairs +41 61 565 62 62 +1 650 624 69 36 http://www.actelion.com
--- End of Message ---
Actelion Pharmaceuticals Ltd Gewerbestrasse 16 Allschwil Switzerland
WKN: 936767; ISIN: CH0010532478; Index: SBIOM, SLIFE, SMCI, SMIEXP, SMIM, SPI, SPIEX; Listed: Main Market in SIX Swiss Exchange;
LINK: http://hugin.info/131801/R/1284612/287837.pdf
Actelion Pharmaceuticals Ltd
http://www.actelion.com
ISIN: CH0010532478
Stock Identifier: XSWX.ATLN
US: OTC:ALIOF
| Tweet |
 |
Related Companies |
>>> Actelion Pharmaceuticals Ltd |
| |
Related Industry Topics: |
European Finance News | |
| |
Diese Seite wurde besucht: (letzten 7 Tagen: 20) (letzten 30 Tagen: 70) (seit Veröffentlichung: 5720) |
Site Search
| DEUTSCH All Languages |
Upcoming WebCasts
 | Mr Mark Paton CEO Cue Energy Resources Tuesday, June 12, 2012 |
 | Mr Alan Hopkins CEO Pan Asia Corporation Tuesday, June 12, 2012 |
 | Mr Barry Dawes Martin Place Securities Tuesday, June 12, 2012 |
 | Dr Andrea Grant CEO Living Cell Technologies Monday, July 02, 2012 |
Companies in the News
Mobile Video TV
|
||
|
||
